Absci Corp (ABSI)
🔔 Watch stock
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Performance
Valuation
Profitability
Balance Sheet & Safety
Growth
Quality & Screener
AI Rating
Sells AIAbsci ist ein KI-natives Biotech, dessen gesamter Umsatz 2025 aus KI-gestützter Wirkstoff-Erzeugung (generative Plattform Origin-1) für Partner stammte — die KI ist nachweislich die alleinige Umsatzquelle, nicht nur ein Etikett.
View the full file — quotes, sources, reviewed filings
„We are a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Our integrated drug creation platform combines Origin-1, our generative design model, with rapid validation using our lab-in-the-loop."
Wir sind ein biopharmazeutisches Unternehmen im klinischen Stadium, das mit einem KI-nativen Ansatz differenzierte Antikörper-Therapeutika entwickelt. Unsere integrierte Wirkstoff-Erzeugungsplattform verbindet Origin-1, unser generatives Designmodell, mit einer schnellen Validierung durch unser lab-in-the-loop.
„For the year ended December 31, 2025, all of our revenue was generated by performing drug creation activities for our partnered programs."
Im Geschäftsjahr zum 31. Dezember 2025 wurde unser gesamter Umsatz durch die Durchführung von Wirkstoff-Erzeugungs-Tätigkeiten für unsere Partnerprogramme erwirtschaftet.
„The Company intends to use the net proceeds from this offering to fund the advancement of ABS-201, the Company's AI-designed anti-PRLR antibody product candidate, across androgenetic alopecia (pattern hair loss) and endometriosis."
Die Gesellschaft beabsichtigt, den Nettoerlös dieser Platzierung zur Weiterentwicklung von ABS-201 zu verwenden, dem KI-designten anti-PRLR-Antikörper-Kandidaten der Gesellschaft, in den Indikationen androgenetische Alopezie (erblich bedingter Haarausfall) und Endometriose.
Filings Reviewed: 10-K 2026-03-24 · 10-Q 2026-05-07 · 10-Q 2025-11-12 · 8-K 2026-06-24 · 10-K 2025-03-18
Rated on July 10, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.25 | – | 1 | 96.70 | -4,358.30 | -17 | -17 |
| 2025: Q1 | -0.21 | – | 1 | 31.30 | -2,234.60 | -22 | -22 |
| 2025: Q2 | -0.24 | – | 1 | -53.30 | -5,155.00 | -17 | -17 |
| 2025: Q3 | -0.20 | – | 0 | -77.80 | -7,594.20 | -25 | -26 |
| 2025: Q4 | -0.20 | – | 1 | -2.30 | -4,548.00 | -29 | -29 |
| 2026: Q1 | -0.19 | – | 0 | -81.80 | -13,767.00 | -26 | -26 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Absci Corporation, ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt verschiedene Antikörpertherapeutika in den USA. Zu den präklinischen Entwicklungsprogrammen gehören ABS-101, das sich in einer klinischen Phase-1-Studie zur Behandlung chronisch-entzündlicher Darmerkrankungen befindet; ABS-201, ein Anti-Prolaktin-Rezeptor…
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 140 |
| Headquarters | Vancouver, WA |
| Website | absci.com |
| IPO Date | 22. Jul 2021 |
| Next Earnings | 11. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Sean McClain | Founder, CEO, President & Director | 1990 |
| Zachariah Jonasson Ph.D. | Chief Business Officer & CFO | 1973 |
| Todd Bedrick CPA | Senior VP & Chief Accounting Officer | – |
| Alexander Khan CPA | CVP of Finance & Head of Investor Relations | – |
| Shelby Walker J.D. | Chief Legal Officer | 1975 |
| Jeanne Schreuder M.B.A., SPHR | Senior Vice President of People & Experience | – |
| Wen Sha | Chief of Staff | – |
| Christine Lemke D.V.M., M.B.A., Ph.D. | Senior Vice President of Portfolio & Growth Strategy | – |
| Ransi Somaratne FACC, M.B.A., M.D. | Chief Medical Officer | 1966 |
| Amer-Denis Akkad Ph.D. | Vice President of Research | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.